Pulmonary Patient Articles & Analysis
24 news found
(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac ...
” “I am also pleased to report that eNOfit™, our novel miniaturized mobile-wearable nitric oxide device designed to provide ’on-the-go’ treatment for patients suffering from severe COPD and ILD (pulmonary fibrosis), is scheduled to enter clinical trials in the next few months. ...
(NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (“PE”). ...
Glenn Crater, CMO at Inversago pointed out: “These encouraging results obtained using a well-accepted preclinical model for lung fibrosis show that zevaquenabant hold promise as a novel treatment option for pulmonary fibrosis. With only two treatments for IPF available, the potential of zevaquenabant in this indication as an add-on therapy is important for ...
"The Adient fully absorbable filter solution creates a new paradigm to protect patients from pulmonary embolus," Dr. Durack shared. "I am thrilled to be part of the collaborative team of Adient, Cordis, and Cordis-X and to see this groundbreaking approach come to fruition." ...
He is also a member of the Board of Directors of the Medical Device Manufacturers Association and Chairman of the Board of Gala Therapeutics, a privately held medical device company that is dedicated to developing disease-modifying therapies for patients with pulmonary diseases. Previously, Mr. Godshall was President, Chief Executive Officer and Director of ...
Arformoterol Tartrate Inhalation Solution 15 mcg (base)/2 ml, Unit-dose Vials are indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.Arformoterol Tartrate Inhalation Solution is for use by nebulization only. ...
Athenson continued, “We are now much closer to improving the lives of 1.2M patients battling severe COPD and ILD (pulmonary fibrosis) and who struggle with each breath to perform the day-to-day activities that most people take for granted. ...
Patients with persistent atrial fibrillation often require electrical isolation beyond simple pulmonary vein isolation and for years we have been seeking a safe, predictable, and effective energy source to do so. ...
Improvements in the field of mechanical circulatory support and the further development of ventricular assist devices enable critically ill heart patients to recover and bridge the often very long waiting periods for a donor heart. Berlin Heart has developed a cannula that intends to a more convenient surgical handling during implantation and an adaptation to the individual needs ...
SAN CARLOS, California, July 28, 2021 — Galaxy Medical announced today that the ECLIPSE-AF 90-day remapping data, presented at the Stanford BioDesign New Arrhythmia Technologies retreat, demonstrated durable lesions and chronic pulmonary vein isolation (PVI). Also, the company has recently treated patients in the same study using CE-Marked catheters and ...
Following implantation, Xeltis’ synthetic restorative pulmonary heart valves evolve into fully functioning, natural heart valves through colonization by the patient’s own tissue. ...
Following successful research into a potential treatment option, PureIMS, Radboudumc and Sever Pharma Solutions (until recently known as Disphar International) are now teaming up to develop an effective cure for this chronic and debilitating disease. Worldwide, over 30,000 patients suffer from Mycobacterium abscessus disease. This number has been steadily rising in recent years, ...
“The ultimate goal in designing and engineering this respiratory solution was to improve clinical workflow efficiency and patient outcomes. We are essentially bringing the pulmonary lab right to the patient’s ...
This innovative therapy was developed to improve the end-organ function and hemodynamics of these patients with univentricular physiology through the support of the sub-pulmonary circulation. ...
Aidoc, the leading provider of enterprise AI solutions, announced today the launch of an industry first: an AI-based automated activation solution that facilitates rapid risk assessment and care coordination for high-risk pulmonary embolism (PE) patients. Aidoc’s PE Care Coordination includes Aidoc’s FDA-cleared solution for triage and notification ...
ByAidoc
The partnership is intended to provide thoracic radiologists and pulmonary embolism management programs timely notification of pulmonary embolism cases combined with automated RV/LV ratio calculations to potentially improve patient severity assessment and expedite treatment. ...
ByAidoc
Applying non-invasive electrical stimulation to the expiratory abdominal muscles may reduce abdominal muscle atrophy and markedly reduce the number of days adult patients require mechanical ventilation – a potentially important finding for weaning ventilated patients, including seriously ill COVID-19 patients, and improving patient outcomes. Liberate Medical today announced the results of ...
AVM has FDA permission to begin clinical trials using AVM0703 to treat patients with COVID-19- and influenza-mediated Acute Respiratory Distress Syndrome (ARDS). ...
Current methods of respiratory muscle training cannot be used when patients are sedated or delirious, which is common among critically ill patients. ...